FPT-CORPORATION
27.5.2024 09:49:29 CEST | Business Wire | Press release
FPT Corporation (FPT), in collaboration with MEDEF International, Business France, the French Chamber of Commerce and Industry (CCIFV), and French Foreign Trade Advisors (CCE), recently organized the France-Vietnam Business Forum in Paris, France. Gathering leading business leaders and tech experts, the event covered topics aiming at accelerating the economic dynamism between Vietnam and France, targeting core industries of both sides, such as aerospace, automotive, manufacturing, energy, and healthcare.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240527659801/en/
The event was attended by the Vietnamese Ambassador to France, Dinh Toan Thang, Business France, MEDEF International, CCI France Vietnam, French Foreign Trade Advisors, and over 100 high-level government officials, business leaders, and tech experts. (Photo: Business Wire)
“Vietnam is one of France’s main economic partners in Southeast Asia, covering a diverse array of sectors with increasing import of Vietnam’s specialised electronic and textile products. In terms of investment, France is the second largest European (EU) investor in Vietnam, generating 50,000 jobs for this market. In 2023, Business France also supported nine Vietnamese investment projects in France,” said Laurent Saint-Martin, CEO of Business France.
Featuring panelists from global businesses and organizations like NVIDIA, FPT, Egis, Thales, Oerlikon, Valeo, OPmobility, and more, the business forum offered attendees the latest updates in next-gen technology and the national socio-economic outlook. Key topics included the economic attractiveness of France and Vietnam, Vietnam’s momentum as a global digital and investment hub, ethical innovation in artificial intelligence, and smart mobility for a sustainable future.
Throughout the panel discussions, FPT has showcased its broad expertise, industry experience, and extensive global outreach, reaffirming its position as a sustainable transformative enabler with cutting-edge and green technologies.
“Vietnam is emerging as a workforce powerhouse and a global hub for investment and technology, notably in digital transformation and green transition, as well as the advancement of AI and the automotive industry. As the country’s leading corporation, FPT’s strategic directions align with the French government and businesses. We have a robust partnership network, a highly skilled workforce, and a solid global presence to bridge the friendship and cooperation between Vietnam and France’s enterprises,” said Pham Minh Tuan, FPT Executive Vice President and FPT Software CEO.
“FPT is the perfect illustration of what France and Vietnam can achieve together. Their 15 years of presence in France with continuous investments since 2008 have created over 120 jobs and the establishment of three subsidiaries. Their renewed strategic partnership with Airbus in 2021 is also an evident symbol of effective cooperation with the European industrial sector,” Laurent added.
FPT now has over 100 local experts working in France's major cities and 500 offshore professionals in Vietnam, focusing on AI, Big Data, BI, SAP, DevSecOps, Cloud, and AUTOSAR services. Its robust competencies are recognized through strategic partnerships with more than 50 French giants across industries.
As part of the company’s global expansion, FPT has been actively involved in M&A deals to amplify its offshore delivery capabilities and local footprint, notably the recent acquisition of an 80% stake in the French IT consulting firm AOSIS. Last year, its French subsidiary also entered the Top 100 ICT Companies in France, targeting to enter the top 50 by 2028.
About FPT Corporation
FPT Corporation (FPT) is a globally leading technology and IT services provider headquartered in Vietnam. FPT operates in three core sectors: Technology, Telecommunications, and Education. During over three decades of development, FPT has constantly provided practical and effective products to millions of people and tens of thousands of business and non-business organizations worldwide, establishing Vietnam’s position on the global tech map. Keeping up with the latest market trends and emerging technologies, FPT has developed the Made-by-FPT ecosystem of services, products, solutions, and platforms, which enables sustainable growth for organizations and businesses and offers distinctive experiences to customers. In 2023, FPT recorded a total revenue of USD 2.17 billion and 48,000+ employees. For more information, please visit https://fpt.com/en.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240527659801/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom